Innate Pharma S.A. (NASDAQ:IPHA) Q3 2022 Earnings Call Transcript
Operator: Hello, and thank you for standing by. My name is Regina and I will be your conference operator today.
Innate Pharma Sa (IPHA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 71,684 | $267 | +390% | 0% |
| 2. | Balyasny Asset Management Dmitry Balyasny | 0 | $0 | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 155,791 | $581,101 | 0% | |
| 2. | 105,534 | $394,000 | 0% | |
| 3. | 49,367 | $184,138 | 0% | |
| 4. | 13,315 | $49,665 | 0% | |
| 5. | 500 | $1,865 | 0% |
News See All
Is Innate Pharma S.A. (IPHA) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Billionaire Hedge Funds
